Identification

Name
Streptomycin
Accession Number
DB01082  (APRD00412)
Type
Small Molecule
Groups
Approved, Vet approved
Description

Streptomycin is an aminoglycoside antibiotic produced by the soil actinomycete Streptomyces griseus. It acts by binding to the 30S ribosomal subunit of susceptible organisms and disrupting the initiation and elongation steps in protein synthesis. It is bactericidal due to effects that are not fully understood.

Structure
Thumb
Synonyms
  • 2,4-diguanidino-3,5,6-trihydroxycyclohexyl 5-deoxy-2-O-(2-deoxy-2-methylamino-alpha-L-glucopyranosyl)-3-C-formyl-beta-L-lyxopentanofuranoside
  • Estreptomicina
  • Streptomicina
  • Streptomyzin
External IDs
NSC-14083
Product Ingredients
IngredientUNIICASInChI Key
Streptomycin SulfateCW25IKJ2023810-74-0CFCMMYICHMLDCC-QXQFOYBSSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Streptomycin for Injection USPPowder, for solution1 gIntramuscularSterimax Inc2001-10-15Not applicableCanada
Streptomycin Sulfate Injection USP 1g/2.5mlLiquid1 gIntramuscularPfizer1993-12-312000-07-26Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
StreptomycinInjection, powder, lyophilized, for solution1 g/1IntramuscularX Gen Pharmaceuticals, Inc.1998-06-30Not applicableUs
Categories
UNII
Y45QSO73OB
CAS number
57-92-1
Weight
Average: 581.5741
Monoisotopic: 581.265669747
Chemical Formula
C21H39N7O12
InChI Key
UCSJYZPVAKXKNQ-HZYVHMACSA-N
InChI
InChI=1S/C21H39N7O12/c1-5-21(36,4-30)16(40-17-9(26-2)13(34)10(31)6(3-29)38-17)18(37-5)39-15-8(28-20(24)25)11(32)7(27-19(22)23)12(33)14(15)35/h4-18,26,29,31-36H,3H2,1-2H3,(H4,22,23,27)(H4,24,25,28)/t5-,6-,7+,8-,9-,10-,11+,12-,13-,14+,15+,16-,17-,18-,21+/m0/s1
IUPAC Name
1-[(1R,2R,3S,4R,5R,6S)-3-carbamimidamido-4-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,5,6-trihydroxycyclohexyl]guanidine
SMILES
CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@]1(O)C=O

Pharmacology

Indication

For the treatment of tuberculosis. May also be used in combination with other drugs to treat tularemia (Francisella tularensis), plague (Yersia pestis), severe M. avium complex, brucellosis, and enterococcal endocarditis (e.g. E. faecalis, E. faecium).

Associated Conditions
Pharmacodynamics

Streptomycin is an aminoglycoside antibiotic. Aminoglycosides work by binding to the bacterial 30S ribosomal subunit, causing misreading of t-RNA, leaving the bacterium unable to synthesize proteins vital to its growth. Aminoglycosides are useful primarily in infections involving aerobic, Gram-negative bacteria, such as Pseudomonas, Acinetobacter, and Enterobacter. In addition, some mycobacteria, including the bacteria that cause tuberculosis, are susceptible to aminoglycosides. Infections caused by Gram-positive bacteria can also be treated with aminoglycosides, but other types of antibiotics are more potent and less damaging to the host. In the past the aminoglycosides have been used in conjunction with penicillin-related antibiotics in streptococcal infections for their synergistic effects, particularly in endocarditis. Aminoglycosides are mostly ineffective against anaerobic bacteria, fungi and viruses.

Mechanism of action

Aminoglycosides like Streptomycin "irreversibly" bind to specific 30S-subunit proteins and 16S rRNA. Specifically Streptomycin binds to four nucleotides of 16S rRNA and a single amino acid of protein S12. This interferes with decoding site in the vicinity of nucleotide 1400 in 16S rRNA of 30S subunit. This region interacts with the wobble base in the anticodon of tRNA. This leads to interference with the initiation complex, misreading of mRNA so incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into nonfunctional monosomes.

TargetActionsOrganism
A30S ribosomal protein S12
inhibitor
Escherichia coli (strain K12)
A16S rRNA
inhibitor
Enteric bacteria and other eubacteria
UProtein-arginine deiminase type-4Not AvailableHuman
Absorption

Rapidly absorbed after intramuscular injection with peak serum concentrations attained after 1 - 2 hours. Not absorbed in the GI tract.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination

Small amounts are excreted in milk, saliva, and sweat. Streptomycin is excreted by glomerular filtration.

Half life

5 - 6 hours in adults with normal renal function

Clearance
Not Available
Toxicity

Nephrotoxic and ototoxic potential. Nephrotoxicity is caused by accumulation of the drug in proximal renal tubular cells, which results in cellular damage. Tubular cells may regenerate despite continued exposure and nephrotoxicity is usually mild and reversible. Streptomycin is the least nephrotoxic of the aminoglycosides owing to the small number of cationic amino groups in its structure. Otoxocity occurs via drug accumulation in the endolymph and perilymph of the inner ear. Accumulation causes irreversible damage to hair cells of the cochlea or summit of the ampullar cristae of the vestibular complex. High frequency hearing loss precedes low frequency hearing loss. Further toxicity may result in retrograde degeneration of the auditory nerve. Vestibular toxicity may result in vertigo, nausea and vomiting, dizziness and loss of balance. LD50=430 mg/kg (Orally in rats with Streptomycin Sulfate); Side effects include nausea, vomiting, and vertigo, paresthesia of face, rash, fever, urticaria, angioneurotic edema, and eosinophilia.

Affected organisms
  • Enteric bacteria and other eubacteria
  • Mycobacteria
  • Mycobacterium tuberculosis
  • Yersinia pestis
  • Francisella tularensis
  • Staphylococcus aureus
  • Enterococcus faecalis
Pathways
PathwayCategory
Streptomycin Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limonene(4R)-limonene may decrease the excretion rate of Streptomycin which could result in a higher serum level.Investigational
AceclofenacAceclofenac may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Investigational
AcemetacinAcemetacin may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Experimental, Investigational
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Streptomycin.Approved
AcetyldigoxinThe serum concentration of Acetyldigoxin can be decreased when it is combined with Streptomycin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
AdapaleneAdapalene may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved
AlclofenacAlclofenac may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Withdrawn
AlcuroniumStreptomycin may increase the respiratory depressant activities of Alcuronium.Experimental
Alendronic acidStreptomycin may increase the hypocalcemic activities of Alendronic acid.Approved
AlminoprofenAlminoprofen may decrease the excretion rate of Streptomycin which could result in a higher serum level.Experimental
AmdinocillinThe serum concentration of Streptomycin can be decreased when it is combined with Amdinocillin.Investigational, Withdrawn
AmikacinThe risk or severity of adverse effects can be increased when Streptomycin is combined with Amikacin.Approved, Investigational, Vet Approved
AmoxicillinThe serum concentration of Streptomycin can be decreased when it is combined with Amoxicillin.Approved, Vet Approved
Amphotericin BAmphotericin B may increase the nephrotoxic activities of Streptomycin.Approved, Investigational
AmpicillinThe serum concentration of Streptomycin can be decreased when it is combined with Ampicillin.Approved, Vet Approved
AndrographolideAndrographolide may decrease the excretion rate of Streptomycin which could result in a higher serum level.Investigational
AnisodamineAnisodamine may decrease the excretion rate of Streptomycin which could result in a higher serum level.Investigational
AntipyrineAntipyrine may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Investigational
ApocyninApocynin may decrease the excretion rate of Streptomycin which could result in a higher serum level.Investigational
ApremilastApremilast may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Investigational
AspoxicillinThe serum concentration of Streptomycin can be decreased when it is combined with Aspoxicillin.Experimental
AtracuriumStreptomycin may increase the respiratory depressant activities of Atracurium.Approved, Experimental, Investigational
Atracurium besylateStreptomycin may increase the respiratory depressant activities of Atracurium besylate.Approved
AtropineThe therapeutic efficacy of Atropine can be decreased when used in combination with Streptomycin.Approved, Vet Approved
AzapropazoneAzapropazone may decrease the excretion rate of Streptomycin which could result in a higher serum level.Withdrawn
AzelastineAzelastine may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved
AzidocillinThe serum concentration of Streptomycin can be decreased when it is combined with Azidocillin.Approved
AzlocillinThe serum concentration of Streptomycin can be decreased when it is combined with Azlocillin.Approved
AzosemideThe serum concentration of Streptomycin can be increased when it is combined with Azosemide.Investigational
BacampicillinThe serum concentration of Streptomycin can be decreased when it is combined with Bacampicillin.Approved, Investigational
BacitracinStreptomycin may increase the nephrotoxic activities of Bacitracin.Approved, Vet Approved
BalsalazideBalsalazide may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Streptomycin.Investigational
BendazacBendazac may decrease the excretion rate of Streptomycin which could result in a higher serum level.Experimental
BenorilateBenorilate may decrease the excretion rate of Streptomycin which could result in a higher serum level.Experimental
BenoxaprofenBenoxaprofen may decrease the excretion rate of Streptomycin which could result in a higher serum level.Withdrawn
BenzatropineThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Streptomycin.Approved
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Streptomycin.Approved, Illicit
BenzydamineBenzydamine may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Streptomycin.Approved
BenzylpenicillinThe serum concentration of Streptomycin can be decreased when it is combined with Benzylpenicillin.Approved, Vet Approved
Benzylpenicilloyl PolylysineThe serum concentration of Streptomycin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
BevoniumBevonium may decrease the excretion rate of Streptomycin which could result in a higher serum level.Experimental
Botulinum Toxin Type AStreptomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BStreptomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved, Investigational
BromfenacBromfenac may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Streptomycin.Approved
BucillamineBucillamine may decrease the excretion rate of Streptomycin which could result in a higher serum level.Investigational
BufexamacBufexamac may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Experimental
BumadizoneBumadizone may decrease the excretion rate of Streptomycin which could result in a higher serum level.Experimental
BumetanideThe serum concentration of Streptomycin can be increased when it is combined with Bumetanide.Approved
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Streptomycin.Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Streptomycin.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Streptomycin.Approved, Investigational
Carbaspirin calciumCarbaspirin calcium may decrease the excretion rate of Streptomycin which could result in a higher serum level.Experimental, Investigational
CarbenicillinThe serum concentration of Streptomycin can be decreased when it is combined with Carbenicillin.Approved, Investigational
Carbenicillin indanylThe serum concentration of Streptomycin can be decreased when it is combined with Carbenicillin indanyl.Approved, Investigational
CarboplatinStreptomycin may increase the ototoxic activities of Carboplatin.Approved
CarfecillinThe serum concentration of Streptomycin can be decreased when it is combined with Carfecillin.Experimental
CarprofenCarprofen may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may decrease the excretion rate of Streptomycin which could result in a higher serum level.Experimental
CefaclorCefaclor may increase the nephrotoxic activities of Streptomycin.Approved
CefamandoleCefamandole may increase the nephrotoxic activities of Streptomycin.Approved, Investigational
CefbuperazoneCefbuperazone may increase the nephrotoxic activities of Streptomycin.Experimental
CefcapeneCefcapene may increase the nephrotoxic activities of Streptomycin.Experimental
CefdinirCefdinir may increase the nephrotoxic activities of Streptomycin.Approved
CefditorenCefditoren may increase the nephrotoxic activities of Streptomycin.Approved, Investigational
CefepimeCefepime may increase the nephrotoxic activities of Streptomycin.Approved, Investigational
CefetametCefetamet may increase the nephrotoxic activities of Streptomycin.Experimental
CefiximeCefixime may increase the nephrotoxic activities of Streptomycin.Approved, Investigational
CefmenoximeCefmenoxime may increase the nephrotoxic activities of Streptomycin.Approved
CefmetazoleCefmetazole may increase the nephrotoxic activities of Streptomycin.Approved, Investigational
CefminoxCefminox may increase the nephrotoxic activities of Streptomycin.Approved
CefodizimeCefodizime may increase the nephrotoxic activities of Streptomycin.Experimental
CefonicidCefonicid may increase the nephrotoxic activities of Streptomycin.Approved, Investigational
CefoperazoneCefoperazone may increase the nephrotoxic activities of Streptomycin.Approved, Investigational
CeforanideCeforanide may increase the nephrotoxic activities of Streptomycin.Approved
CefotaximeCefotaxime may increase the nephrotoxic activities of Streptomycin.Approved
CefotetanCefotetan may increase the nephrotoxic activities of Streptomycin.Approved
CefotiamCefotiam may increase the nephrotoxic activities of Streptomycin.Approved, Investigational
CefoxitinCefoxitin may increase the nephrotoxic activities of Streptomycin.Approved
CefozopranCefozopran may increase the nephrotoxic activities of Streptomycin.Experimental
CefpiramideCefpiramide may increase the nephrotoxic activities of Streptomycin.Approved
CefpiromeCefpirome may increase the nephrotoxic activities of Streptomycin.Approved
CefpodoximeCefpodoxime may increase the nephrotoxic activities of Streptomycin.Approved, Vet Approved
CefprozilCefprozil may increase the nephrotoxic activities of Streptomycin.Approved
CefsulodinCefsulodin may increase the nephrotoxic activities of Streptomycin.Experimental
CeftazidimeCeftazidime may increase the nephrotoxic activities of Streptomycin.Approved
CeftibutenCeftibuten may increase the nephrotoxic activities of Streptomycin.Approved, Investigational
CeftizoximeCeftizoxime may increase the nephrotoxic activities of Streptomycin.Approved, Investigational
CeftriaxoneCeftriaxone may increase the nephrotoxic activities of Streptomycin.Approved
CefuroximeCefuroxime may increase the nephrotoxic activities of Streptomycin.Approved
CelecoxibCelecoxib may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Streptomycin.Approved
ChloroquineChloroquine may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Streptomycin.Approved
ChlorthalidoneThe serum concentration of Streptomycin can be increased when it is combined with Chlorthalidone.Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved
CisatracuriumStreptomycin may increase the respiratory depressant activities of Cisatracurium.Approved
CisplatinCisplatin may increase the nephrotoxic activities of Streptomycin.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Streptomycin.Approved, Investigational
ClindamycinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Streptomycin.Approved, Vet Approved
Clodronic AcidStreptomycin may increase the hypocalcemic activities of Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinClonixin may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved
CloxacillinThe serum concentration of Streptomycin can be decreased when it is combined with Cloxacillin.Approved, Investigational, Vet Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Streptomycin.Approved, Illicit
ColistimethateStreptomycin may increase the nephrotoxic activities of Colistimethate.Approved, Vet Approved
CurcuminCurcumin may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Investigational
CyclacillinThe serum concentration of Streptomycin can be decreased when it is combined with Cyclacillin.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Streptomycin.Approved
CyclosporineThe risk or severity of adverse effects can be increased when Streptomycin is combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinThe serum concentration of Cymarin can be decreased when it is combined with Streptomycin.Experimental
DecamethoniumStreptomycin may increase the respiratory depressant activities of Decamethonium.Approved
DeslanosideThe serum concentration of Deslanoside can be decreased when it is combined with Streptomycin.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Streptomycin is combined with Desvenlafaxine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Streptomycin.Approved
DiclofenacThe risk or severity of nephrotoxicity can be increased when Diclofenac is combined with Streptomycin.Approved, Vet Approved
DicloxacillinThe serum concentration of Streptomycin can be decreased when it is combined with Dicloxacillin.Approved, Investigational, Vet Approved
DifenpiramideDifenpiramide may decrease the excretion rate of Streptomycin which could result in a higher serum level.Experimental
DiflunisalDiflunisal may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Investigational
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Streptomycin.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Streptomycin.Approved
Digoxin Immune Fab (Ovine)The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Streptomycin.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Streptomycin.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Streptomycin.Approved, Investigational
Domoic AcidStreptomycin may increase the respiratory depressant activities of Domoic Acid.Experimental
DotarizineThe risk or severity of adverse effects can be increased when Streptomycin is combined with Dotarizine.Investigational
DoxacuriumStreptomycin may increase the respiratory depressant activities of Doxacurium chloride.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Streptomycin.Approved, Vet Approved
DroxicamDroxicam may decrease the excretion rate of Streptomycin which could result in a higher serum level.Withdrawn
DuvelisibDuvelisib may decrease the excretion rate of Streptomycin which could result in a higher serum level.Investigational
E-6201E-6201 may decrease the excretion rate of Streptomycin which could result in a higher serum level.Investigational
EperisoneThe risk or severity of adverse effects can be increased when Eperisone is combined with Streptomycin.Approved, Investigational
EpicillinThe serum concentration of Streptomycin can be decreased when it is combined with Epicillin.Experimental
EpirizoleEpirizole may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved
Etacrynic acidThe serum concentration of Streptomycin can be increased when it is combined with Etacrynic acid.Approved, Investigational
EtanerceptEtanercept may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Investigational
EthanolStreptomycin may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthenzamideEthenzamide may decrease the excretion rate of Streptomycin which could result in a higher serum level.Experimental
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Streptomycin.Approved
Etidronic acidStreptomycin may increase the hypocalcemic activities of Etidronic acid.Approved
EtodolacEtodolac may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Investigational
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Streptomycin.Approved
EtoricoxibEtoricoxib may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the excretion rate of Streptomycin which could result in a higher serum level.Investigational, Nutraceutical
ExisulindExisulind may decrease the excretion rate of Streptomycin which could result in a higher serum level.Investigational
FelbinacFelbinac may decrease the excretion rate of Streptomycin which could result in a higher serum level.Experimental
FenbufenFenbufen may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved
FenoprofenFenoprofen may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Streptomycin.Approved, Illicit, Investigational, Vet Approved
FentiazacFentiazac may decrease the excretion rate of Streptomycin which could result in a higher serum level.Experimental
FeprazoneFeprazone may decrease the excretion rate of Streptomycin which could result in a higher serum level.Experimental
Ferulic acidFerulic acid may decrease the excretion rate of Streptomycin which could result in a higher serum level.Experimental
FloctafenineFloctafenine may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Withdrawn
FlomoxefFlomoxef may increase the nephrotoxic activities of Streptomycin.Investigational
FlucloxacillinThe serum concentration of Streptomycin can be decreased when it is combined with Flucloxacillin.Approved, Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Streptomycin.Approved
FlunixinFlunixin may decrease the excretion rate of Streptomycin which could result in a higher serum level.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the excretion rate of Streptomycin which could result in a higher serum level.Experimental
FluoxetineThe risk or severity of adverse effects can be increased when Streptomycin is combined with Fluoxetine.Approved, Vet Approved
FlurbiprofenFlurbiprofen may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Streptomycin.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Streptomycin.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Streptomycin is combined with Fluvoxamine.Approved, Investigational
FoscarnetFoscarnet may increase the nephrotoxic activities of Streptomycin.Approved
FurosemideThe serum concentration of Streptomycin can be increased when it is combined with Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Streptomycin.Approved, Investigational
GallamineStreptomycin may increase the respiratory depressant activities of Gallamine.Experimental
Gallamine TriethiodideStreptomycin may increase the respiratory depressant activities of Gallamine Triethiodide.Approved
GitoformateThe serum concentration of Gitoformate can be decreased when it is combined with Streptomycin.Experimental
GuacetisalGuacetisal may decrease the excretion rate of Streptomycin which could result in a higher serum level.Experimental
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Streptomycin.Approved, Investigational
HigenamineHigenamine may decrease the excretion rate of Streptomycin which could result in a higher serum level.Investigational
HydrocodoneStreptomycin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe serum concentration of Streptomycin can be increased when it is combined with Hydroflumethiazide.Approved, Investigational
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Streptomycin.Approved
HyoscyamineThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Streptomycin.Approved
IbandronateThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Streptomycin is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Streptomycin.Approved
IbuproxamIbuproxam may decrease the excretion rate of Streptomycin which could result in a higher serum level.Withdrawn
IcatibantIcatibant may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Investigational
Imidazole salicylateImidazole salicylate may decrease the excretion rate of Streptomycin which could result in a higher serum level.Experimental
IndobufenIndobufen may decrease the excretion rate of Streptomycin which could result in a higher serum level.Investigational
IndomethacinIndomethacin may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Investigational
IndoprofenIndoprofen may decrease the excretion rate of Streptomycin which could result in a higher serum level.Withdrawn
IpratropiumThe therapeutic efficacy of Ipratropium can be decreased when used in combination with Streptomycin.Approved
IsoxicamIsoxicam may decrease the excretion rate of Streptomycin which could result in a higher serum level.Withdrawn
KebuzoneKebuzone may decrease the excretion rate of Streptomycin which could result in a higher serum level.Experimental
KetoprofenKetoprofen may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
KetorolacThe risk or severity of nephrotoxicity can be increased when Ketorolac is combined with Streptomycin.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Streptomycin.Approved, Investigational
Lanatoside CThe serum concentration of Lanatoside C can be decreased when it is combined with Streptomycin.Experimental
LatamoxefLatamoxef may increase the nephrotoxic activities of Streptomycin.Approved, Investigational
LeflunomideLeflunomide may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Streptomycin.Approved, Investigational
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Streptomycin.Approved
LisofyllineLisofylline may decrease the excretion rate of Streptomycin which could result in a higher serum level.Investigational
LonazolacLonazolac may decrease the excretion rate of Streptomycin which could result in a higher serum level.Experimental
LoracarbefLoracarbef may increase the nephrotoxic activities of Streptomycin.Investigational, Withdrawn
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Streptomycin.Approved, Investigational
LornoxicamLornoxicam may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Investigational
LoxoprofenLoxoprofen may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Investigational
LumiracoxibLumiracoxib may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Investigational
Magnesium carbonateThe risk or severity of adverse effects can be increased when Streptomycin is combined with Magnesium carbonate.Approved, Investigational
Magnesium citrateThe risk or severity of adverse effects can be increased when Streptomycin is combined with Magnesium citrate.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Streptomycin is combined with Magnesium hydroxide.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved
Magnesium sulfateThe therapeutic efficacy of Streptomycin can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Streptomycin is combined with Magnesium Trisilicate.Approved
MannitolMannitol may increase the nephrotoxic activities of Streptomycin.Approved, Investigational
MasoprocolMasoprocol may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Investigational
MecamylamineStreptomycin may increase the neuromuscular blocking activities of Mecamylamine.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Streptomycin.Approved
Meclofenamic acidMeclofenamic acid may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved
MeloxicamMeloxicam may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
MesalazineMesalazine may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved
MetamizoleMetamizole may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Investigational, Withdrawn
MetampicillinThe serum concentration of Streptomycin can be decreased when it is combined with Metampicillin.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Streptomycin.Approved
MethyclothiazideThe serum concentration of Streptomycin can be increased when it is combined with Methyclothiazide.Approved
MeticillinThe serum concentration of Streptomycin can be decreased when it is combined with Meticillin.Approved, Investigational
MetildigoxinThe serum concentration of Metildigoxin can be decreased when it is combined with Streptomycin.Experimental
MetocurineStreptomycin may increase the respiratory depressant activities of Metocurine.Approved
Metocurine IodideStreptomycin may increase the respiratory depressant activities of Metocurine Iodide.Approved, Withdrawn
MezlocillinThe serum concentration of Streptomycin can be decreased when it is combined with Mezlocillin.Approved, Investigational
MivacuriumStreptomycin may increase the respiratory depressant activities of Mivacurium.Approved
MizoribineMizoribine may decrease the excretion rate of Streptomycin which could result in a higher serum level.Investigational
MofebutazoneMofebutazone may decrease the excretion rate of Streptomycin which could result in a higher serum level.Experimental
Mycophenolate mofetilMycophenolate mofetil may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved
NabumetoneNabumetone may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved
NafamostatNafamostat may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Investigational
NafcillinThe serum concentration of Streptomycin can be decreased when it is combined with Nafcillin.Approved, Investigational
NaftifineNaftifine may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved
NaproxenThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Streptomycin.Approved, Vet Approved
NeomycinThe risk or severity of adverse effects can be increased when Streptomycin is combined with Neomycin.Approved, Vet Approved
NeosaxitoxinStreptomycin may increase the respiratory depressant activities of Neosaxitoxin.Investigational
NepafenacNepafenac may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Investigational
NicotineThe risk or severity of adverse effects can be increased when Streptomycin is combined with Nicotine.Approved
NifenazoneNifenazone may decrease the excretion rate of Streptomycin which could result in a higher serum level.Experimental
Niflumic AcidNiflumic Acid may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved
NimesulideThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Streptomycin.Approved, Investigational, Withdrawn
NitroaspirinNitroaspirin may decrease the excretion rate of Streptomycin which could result in a higher serum level.Investigational
OleandrinThe serum concentration of Oleandrin can be decreased when it is combined with Streptomycin.Experimental, Investigational
OlopatadineOlopatadine may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved
OlsalazineOlsalazine may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Streptomycin.Approved
OrgoteinOrgotein may decrease the excretion rate of Streptomycin which could result in a higher serum level.Vet Approved
OtiloniumThe therapeutic efficacy of Otilonium can be decreased when used in combination with Streptomycin.Experimental, Investigational
OuabainThe serum concentration of Ouabain can be decreased when it is combined with Streptomycin.Approved
OxacillinThe serum concentration of Streptomycin can be decreased when it is combined with Oxacillin.Approved, Investigational
OxaprozinOxaprozin may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Streptomycin.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Streptomycin.Approved, Investigational, Vet Approved
OxyphenbutazoneOxyphenbutazone may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Withdrawn
PalmidrolPalmidrol may decrease the excretion rate of Streptomycin which could result in a higher serum level.Experimental, Nutraceutical
PamidronateStreptomycin may increase the hypocalcemic activities of Pamidronate.Approved
PancuroniumStreptomycin may increase the respiratory depressant activities of Pancuronium.Approved
ParecoxibParecoxib may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved
ParomomycinThe risk or severity of adverse effects can be increased when Streptomycin is combined with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Streptomycin is combined with Paroxetine.Approved, Investigational
ParthenolideParthenolide may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Investigational
PenamecillinThe serum concentration of Streptomycin can be decreased when it is combined with Penamecillin.Experimental
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Streptomycin.Experimental
PeruvosideThe serum concentration of Peruvoside can be decreased when it is combined with Streptomycin.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Streptomycin.Approved, Investigational
PhenoxymethylpenicillinThe serum concentration of Streptomycin can be decreased when it is combined with Phenoxymethylpenicillin.Approved, Vet Approved
PhenylbutazonePhenylbutazone may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Streptomycin.Approved
PimecrolimusPimecrolimus may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Investigational
PipecuroniumStreptomycin may increase the respiratory depressant activities of Pipecuronium.Approved
PiperacillinThe serum concentration of Streptomycin can be decreased when it is combined with Piperacillin.Approved
PiretanideThe serum concentration of Streptomycin can be increased when it is combined with Piretanide.Approved
PirfenidonePirfenidone may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Investigational
PiroxicamPiroxicam may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Investigational
PirprofenPirprofen may decrease the excretion rate of Streptomycin which could result in a higher serum level.Experimental
PivampicillinThe serum concentration of Streptomycin can be decreased when it is combined with Pivampicillin.Approved
PivmecillinamThe serum concentration of Streptomycin can be decreased when it is combined with Pivmecillinam.Approved
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Streptomycin is combined with Polymyxin B Sulfate.Approved, Vet Approved
PramipexoleStreptomycin may increase the sedative activities of Pramipexole.Approved, Investigational
PranoprofenPranoprofen may decrease the excretion rate of Streptomycin which could result in a higher serum level.Experimental, Investigational
PregabalinThe therapeutic efficacy of Streptomycin can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
Procaine benzylpenicillinThe serum concentration of Streptomycin can be decreased when it is combined with Procaine benzylpenicillin.Approved, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Streptomycin.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the excretion rate of Streptomycin which could result in a higher serum level.Experimental
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Streptomycin.Approved, Investigational
PropacetamolPropacetamol may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Investigational
PropicillinThe serum concentration of Streptomycin can be decreased when it is combined with Propicillin.Experimental
PropyphenazonePropyphenazone may decrease the excretion rate of Streptomycin which could result in a higher serum level.Experimental
ProquazoneProquazone may decrease the excretion rate of Streptomycin which could result in a higher serum level.Experimental
ProscillaridinThe serum concentration of Proscillaridin can be decreased when it is combined with Streptomycin.Experimental
PseudoephedrineThe risk or severity of adverse effects can be increased when Streptomycin is combined with Pseudoephedrine.Approved
PTC299PTC299 may decrease the excretion rate of Streptomycin which could result in a higher serum level.Investigational
PyrantelThe therapeutic efficacy of Pyrantel can be increased when used in combination with Streptomycin.Approved, Vet Approved
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Streptomycin.Approved
QuinethazoneThe serum concentration of Streptomycin can be increased when it is combined with Quinethazone.Approved
RapacuroniumStreptomycin may increase the respiratory depressant activities of Rapacuronium.Withdrawn
ResveratrolResveratrol may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Experimental, Investigational
RisedronateStreptomycin may increase the hypocalcemic activities of Risedronate.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Streptomycin is combined with Rizatriptan.Approved
RocuroniumStreptomycin may increase the respiratory depressant activities of Rocuronium.Approved
RofecoxibRofecoxib may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Investigational, Withdrawn
RopiniroleStreptomycin may increase the sedative activities of Ropinirole.Approved, Investigational
SalicylamideSalicylamide may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved
Salicylic acidThe risk or severity of nephrotoxicity can be increased when Salicylic acid is combined with Streptomycin.Approved, Investigational, Vet Approved
SalsalateSalsalate may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Streptomycin.Approved, Investigational
SemapimodSemapimod may decrease the excretion rate of Streptomycin which could result in a higher serum level.Investigational
SeratrodastSeratrodast may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved
SerrapeptaseSerrapeptase may decrease the excretion rate of Streptomycin which could result in a higher serum level.Investigational
SRT501SRT501 may decrease the excretion rate of Streptomycin which could result in a higher serum level.Investigational
SuccinylcholineStreptomycin may increase the respiratory depressant activities of Succinylcholine.Approved
SulbenicillinThe serum concentration of Streptomycin can be decreased when it is combined with Sulbenicillin.Experimental
SulfasalazineThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Streptomycin.Approved
SulindacThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Streptomycin.Approved, Investigational
SultamicillinThe serum concentration of Streptomycin can be decreased when it is combined with Sultamicillin.Approved, Investigational
SumatriptanThe risk or severity of adverse effects can be increased when Streptomycin is combined with Sumatriptan.Approved, Investigational
SuprofenSuprofen may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the excretion rate of Streptomycin which could result in a higher serum level.Experimental
TalampicillinThe serum concentration of Streptomycin can be decreased when it is combined with Talampicillin.Experimental
TarenflurbilTarenflurbil may decrease the excretion rate of Streptomycin which could result in a higher serum level.Investigational
Technetium Tc-99m etidronateStreptomycin may increase the hypocalcemic activities of Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateStreptomycin may increase the hypocalcemic activities of Technetium Tc-99m medronate.Approved
TenidapTenidap may decrease the excretion rate of Streptomycin which could result in a higher serum level.Experimental
Tenofovir disoproxilThe serum concentration of Streptomycin can be increased when it is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamTenoxicam may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved
TepoxalinTepoxalin may decrease the excretion rate of Streptomycin which could result in a higher serum level.Vet Approved
TeriflunomideTeriflunomide may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved
TetracyclineThe risk or severity of adverse effects can be increased when Streptomycin is combined with Tetracycline.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Streptomycin.Investigational
Tiaprofenic acidTiaprofenic acid may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved
TicarcillinThe serum concentration of Streptomycin can be decreased when it is combined with Ticarcillin.Approved, Investigational, Vet Approved
Tiludronic acidStreptomycin may increase the hypocalcemic activities of Tiludronic acid.Approved, Investigational, Vet Approved
TinoridineTinoridine may decrease the excretion rate of Streptomycin which could result in a higher serum level.Investigational
Tolfenamic AcidThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Streptomycin.Approved, Investigational
TolmetinTolmetin may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Streptomycin.Approved
TorasemideThe serum concentration of Streptomycin can be increased when it is combined with Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Streptomycin.Approved, Investigational
TribenosideTribenoside may decrease the excretion rate of Streptomycin which could result in a higher serum level.Experimental
TrichlormethiazideThe serum concentration of Streptomycin can be increased when it is combined with Trichlormethiazide.Approved, Vet Approved
TrimethadioneThe risk or severity of adverse effects can be increased when Trimethadione is combined with Streptomycin.Approved
TriptolideTriptolide may decrease the excretion rate of Streptomycin which could result in a higher serum level.Investigational
Trolamine salicylateThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Streptomycin.Approved
TrospiumThe therapeutic efficacy of Trospium can be decreased when used in combination with Streptomycin.Approved
TubocurarineStreptomycin may increase the respiratory depressant activities of Tubocurarine.Approved
ValdecoxibValdecoxib may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Investigational, Withdrawn
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Streptomycin.Approved, Investigational
VancomycinThe risk or severity of adverse effects can be increased when Streptomycin is combined with Vancomycin.Approved
VecuroniumThe therapeutic efficacy of Vecuronium can be increased when used in combination with Streptomycin.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Streptomycin is combined with Venlafaxine.Approved
VinpocetineThe risk or severity of adverse effects can be increased when Vinpocetine is combined with Streptomycin.Investigational
ZaltoprofenZaltoprofen may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Streptomycin.Approved
ZileutonZileuton may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Investigational, Withdrawn
Zoledronic acidThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Streptomycin is combined with Zoledronic acid.Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Streptomycin is combined with Zolmitriptan.Approved, Investigational
ZolpidemStreptomycin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZomepiracZomepirac may decrease the excretion rate of Streptomycin which could result in a higher serum level.Withdrawn
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Streptomycin.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Arnold L. Demain, Kozo Nagaoka, "Derivatives of streptomycin and method of producing streptomycin derivatives by mutational biosynthesis." U.S. Patent US3993544, issued November 23, 1976.

US3993544
General References
Not Available
External Links
Human Metabolome Database
HMDB0015214
KEGG Compound
C00413
PubChem Compound
19649
PubChem Substance
46506845
ChemSpider
18508
BindingDB
50103513
ChEBI
17076
ChEMBL
CHEMBL372795
Therapeutic Targets Database
DAP000144
PharmGKB
PA451512
HET
SRY
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Streptomycin
ATC Codes
J01GA01 — StreptomycinJ04AM01 — Streptomycin and isoniazidA07AA04 — StreptomycinA07AA54 — Streptomycin, combinations
AHFS Codes
  • 08:12.02 — Aminoglycosides
PDB Entries
1fjg / 1nta / 1ntb / 3hav / 4dr3 / 4dr5 / 4dr6 / 4dr7 / 4duz / 4dv1
show 10 more
MSDS
Download (73.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentOsteomyelitis1
2CompletedTreatmentInfection, Mycobacterium Avium-Intracellulare1
2, 3Active Not RecruitingTreatmentMycobacterium Ulcerans Infection1
2, 3CompletedTreatmentPlague1
3RecruitingTreatmentMDR-TB1
Not AvailableCompletedNot AvailablePatients Colonized by Klebsiella Pneumoniae1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis1
Not AvailableCompletedTreatmentTuberculosis, Pulmonary1
Not AvailableRecruitingNot AvailableTuberculosis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Ben Venue Laboratories Inc.
  • Gallipot
  • Sanofi-Aventis Inc.
  • X-Gen Pharmaceuticals
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for solutionIntramuscular1 g/1
Powder, for solutionIntramuscular1 g
LiquidIntramuscular1 g
Prices
Unit descriptionCostUnit
Streptomycin sulf 1 gm vial14.65USD vial
Streptomycin sulfate powder0.82USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP-6.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility12.8 mg/mLALOGPS
logP-2.6ALOGPS
logP-7.7ChemAxon
logS-1.7ALOGPS
pKa (Strongest Acidic)10.88ChemAxon
pKa (Strongest Basic)11.9ChemAxon
Physiological Charge3ChemAxon
Hydrogen Acceptor Count19ChemAxon
Hydrogen Donor Count14ChemAxon
Polar Surface Area331.43 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity149.47 m3·mol-1ChemAxon
Polarizability55.76 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8824
Blood Brain Barrier-0.9712
Caco-2 permeable-0.6968
P-glycoprotein substrateSubstrate0.5531
P-glycoprotein inhibitor INon-inhibitor0.7577
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterNon-inhibitor0.7782
CYP450 2C9 substrateNon-substrate0.7053
CYP450 2D6 substrateNon-substrate0.8177
CYP450 3A4 substrateNon-substrate0.5275
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9072
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8867
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8818
Ames testAMES toxic0.9107
CarcinogenicityNon-carcinogens0.9528
BiodegradationNot ready biodegradable0.9821
Rat acute toxicity1.8409 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9924
hERG inhibition (predictor II)Non-inhibitor0.9009
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - DI-ESI-Ion Trap , PositiveLC-MS/MSNot Available
MS/MS Spectrum - DI-ESI-Hybrid FT , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-001i-0000090000-37fcf4def2f5e472aa90
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-03di-0091010000-39300aec20bda5d23649
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-03di-0090000000-34b8374e2a80e4cb95ec
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-03xr-1090000000-0d28a95c3d70165872c6
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-014j-5190000000-87daef600d1a1a4b52d8
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-001i-0200090000-e3f4de9e437da47f8b50
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-01q9-0911281000-307d692fcab3f0a93c0a
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-03e9-0900250000-1e9e471e29850e7a3023
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-001i-0660090000-e0be715ff2ef7bceed6e
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0udi-0090000000-da49dca8f3e875260220
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0006-0090000000-51b8b9878643820d5652
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0729-6940300000-cbd7d78f026f93380976
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00dj-9750000000-ea4bfbc8bf26152232f7
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00dj-9100000000-e44f835436ca5aa376a5
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0usi-9040000000-4cb87273cf38a98ccf69
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-001i-0000090000-f0c24196329215da6048
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-001i-0000090000-0de059c38cbd52e00cce
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-01q9-0182190000-46e9dfef9871c913947b
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03dj-1391000000-ae846bc34742e8a119c8
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0fdt-4790000000-c949fbfe981dc5f039e8

Taxonomy

Description
This compound belongs to the class of organic compounds known as aminocyclitol glycosides. These are organic compounds containing an amicocyclitol moiety glycosidically linked to a carbohydrate moiety. There are two major classes of aminoglycosides containing a 2-streptamine core. They are called 4,5- and 4,6-disubstituted 2-deoxystreptamines.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Aminocyclitol glycosides
Alternative Parents
O-glycosyl compounds / Cyclohexanols / Cyclitols and derivatives / Monosaccharides / Oxanes / Tetrahydrofurans / Tertiary alcohols / Guanidines / 1,2-aminoalcohols / Oxacyclic compounds
show 10 more
Substituents
Amino cyclitol glycoside / Glycosyl compound / O-glycosyl compound / Cyclohexanol / Monosaccharide / Cyclitol or derivatives / Oxane / Cyclic alcohol / Tertiary alcohol / Tetrahydrofuran
show 23 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
antibiotic antifungal drug, antibiotic fungicide, streptomycins (CHEBI:17076) / Streptidines, Antibiotic fungicides (C00413)

Targets

Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Trna binding
Specific Function
With S4 and S5 plays an important role in translational accuracy.Interacts with and stabilizes bases of the 16S rRNA that are involved in tRNA selection in the A site and with the mRNA backbone. Lo...
Gene Name
rpsL
Uniprot ID
P0A7S3
Uniprot Name
30S ribosomal protein S12
Molecular Weight
13736.995 Da
References
  1. Mieskes KT, Rusch-Gerdes S, Truffot-Pernot C, Feldmann K, Tortoli E, Casal M, Loscher T, Rinder H: Rapid, simple, and culture-independent detection of rpsL codon 43 mutations that are highly predictive of streptomycin resistance in Mycobacterium tuberculosis. Am J Trop Med Hyg. 2000 Jul-Aug;63(1-2):56-60. [PubMed:11357996]
  2. Kenney TJ, Churchward G: Cloning and sequence analysis of the rpsL and rpsG genes of Mycobacterium smegmatis and characterization of mutations causing resistance to streptomycin. J Bacteriol. 1994 Oct;176(19):6153-6. [PubMed:7928982]
  3. Fukuda M, Koga H, Ohno H, Ogawa K, Yang B, Miyamoto J, Tomono K, Kohno S: [Relationship between streptomycin susceptibility and rpsL mutations of Mycobacterium tuberculosis strains]. Kekkaku. 1997 Sep;72(9):507-13. [PubMed:9364810]
2. 16S rRNA
Kind
Nucleotide
Organism
Enteric bacteria and other eubacteria
Pharmacological action
Yes
Actions
Inhibitor
References
  1. Okamoto S, Tamaru A, Nakajima C, Nishimura K, Tanaka Y, Tokuyama S, Suzuki Y, Ochi K: Loss of a conserved 7-methylguanosine modification in 16S rRNA confers low-level streptomycin resistance in bacteria. Mol Microbiol. 2007 Feb;63(4):1096-106. [PubMed:17238915]
  2. Nishimura K, Hosaka T, Tokuyama S, Okamoto S, Ochi K: Mutations in rsmG, encoding a 16S rRNA methyltransferase, result in low-level streptomycin resistance and antibiotic overproduction in Streptomyces coelicolor A3(2). J Bacteriol. 2007 May;189(10):3876-83. Epub 2007 Mar 23. [PubMed:17384192]
  3. Vila-Sanjurjo A, Lu Y, Aragonez JL, Starkweather RE, Sasikumar M, O'Connor M: Modulation of 16S rRNA function by ribosomal protein S12. Biochim Biophys Acta. 2007 Jul-Aug;1769(7-8):462-71. Epub 2007 Apr 20. [PubMed:17512991]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Protein-arginine deiminase activity
Specific Function
Catalyzes the citrullination/deimination of arginine residues of proteins such as histones, thereby playing a key role in histone code and regulation of stem cell maintenance. Citrullinates histone...
Gene Name
PADI4
Uniprot ID
Q9UM07
Uniprot Name
Protein-arginine deiminase type-4
Molecular Weight
74078.65 Da
References
  1. Knuckley B, Luo Y, Thompson PR: Profiling Protein Arginine Deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors. Bioorg Med Chem. 2008 Jan 15;16(2):739-45. Epub 2007 Oct 13. [PubMed:17964793]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Jariyawat S, Sekine T, Takeda M, Apiwattanakul N, Kanai Y, Sophasan S, Endou H: The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1. J Pharmacol Exp Ther. 1999 Aug;290(2):672-7. [PubMed:10411577]

Drug created on June 13, 2005 07:24 / Updated on August 14, 2018 04:31